HCA Healthcare, Inc. HCA

Zacks Investment Research 9 nov

Stock markets declined for the week ended November 6, with the Nasdaq, S&P 500, and Dow falling 3.4%, 2.7%, and 0.9% respectively, as investors reassessed AI valuations and infrastructure spending. A partial recovery on Friday was driven by stronger-than-expected October employment data, though concerns about potential Fed rate hikes persisted. Zacks highlighted several outperforming stocks across its various portfolios, including HCA Healthcare and Ulta Beauty from its Focus List, Accenture from its ECAP portfolio, and dividend stocks like Procter & Gamble and Automatic Data Processing.

Zacks Investment Research 6 nov

Humana (HUM) reported Q3 2026 adjusted loss of $0.70 per share, beating estimates, with revenues surging 26.4% to $40.83B driven by Medicare membership growth and higher premiums. The company raised its 2026 adjusted EPS guidance to at least $9.50 and projects revenues of at least $160B, though rising benefit costs and deteriorating benefit ratios remain concerns.

Zacks Investment Research 6 nov

A $1,000 investment in HCA Healthcare made in November 2016 would be worth $6,736.76 as of November 6, 2026, representing a 573.68% gain and significantly outperforming the S&P 500's 252.67% return. The largest non-governmental acute care hospital operator in the U.S. has benefited from rising patient admissions and improved operational efficiency, though analysts maintain a Neutral rating citing concerns about exchange-related coverage losses, weak elective surgery trends, and potential Medicaid payment changes in 2027.

Zacks Investment Research 5 nov

Following Democrats' strong performance in the 2026 midterm elections, AI and data center stocks face increased regulatory risks, particularly in key states like Texas where data center moratoriums are being considered. Investors are advised to diversify toward consumer-focused ETFs, which are supported by strong consumer spending, robust holiday sales forecasts, and potential healthcare policy improvements.

Zacks Investment Research 29 oct

Tenet Healthcare (THC) delivered robust third-quarter 2026 results with adjusted EPS of $6.64, up 79.5% year-over-year and beating estimates by 44.4%. Revenues grew 6.5% to $5.6 billion, driven by higher admissions, pricing strength, and disciplined cost management. The company raised its full-year 2026 adjusted EPS guidance to $22.05-$23.01 and EBITDA guidance to $5.05-$5.2 billion. Hospital EBITDA surged 34.8% to $818 million, while the company generated $1.1 billion in free cash flow and repurchased $255 million in shares.